Multi-parameter optimization: identifying high quality compounds with a balance of properties.
暂无分享,去创建一个
[1] Matthew Segall,et al. Beyond Profiling: Using ADMET Models to Guide Decisions , 2009, Chemistry & biodiversity.
[2] Yvonne C. Martin,et al. Application of Belief Theory to Similarity Data Fusion for Use in Analog Searching and Lead Hopping , 2008, J. Chem. Inf. Model..
[3] Christopher W Murray,et al. Fragment-based lead discovery: leads by design. , 2005, Drug discovery today.
[4] Constantinos S. Pattichis,et al. De Novo Drug Design Using Multiobjective Evolutionary Graphs , 2009, J. Chem. Inf. Model..
[5] Thomas J. Raub,et al. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. , 1989, Gastroenterology.
[6] C. Humblet,et al. Escape from flatland: increasing saturation as an approach to improving clinical success. , 2009, Journal of medicinal chemistry.
[7] Li Xing,et al. Influence of molecular flexibility and polar surface area metrics on oral bioavailability in the rat. , 2004, Journal of medicinal chemistry.
[8] Ross McGuire,et al. A molecular informatics view on best practice in multi-parameter compound optimization. , 2011, Drug discovery today.
[9] David E. Clark,et al. Evolutionary algorithms in computer-aided molecular design , 1996, J. Comput. Aided Mol. Des..
[10] Peter J. Fleming,et al. Genetic Algorithms for Multiobjective Optimization: FormulationDiscussion and Generalization , 1993, ICGA.
[11] Jeffrey R. Huth,et al. Enhancement of chemical rules for predicting compound reactivity towards protein thiol groups , 2007, J. Comput. Aided Mol. Des..
[12] A. Hopkins,et al. Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.
[13] Gareth Jones,et al. Genetic and Evolutionary Algorithms , 2002 .
[14] R. W. Hansen,et al. The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.
[15] David A. Price,et al. Role of Physicochemical Properties and Ligand Lipophilicity Efficiency in Addressing Drug Safety Risks , 2010 .
[16] György G Ferenczy,et al. Thermodynamics guided lead discovery and optimization. , 2010, Drug discovery today.
[17] Nigel Greene,et al. Physicochemical drug properties associated with in vivo toxicological outcomes: a review , 2009, Expert opinion on drug metabolism & toxicology.
[18] Nathan Brown,et al. Molecular optimization using computational multi-objective methods. , 2007, Current opinion in drug discovery & development.
[19] Dimitris K. Agrafiotis,et al. The Diversity of Chemical Libraries , 2002 .
[20] Johann Gasteiger,et al. Structure and reaction based evaluation of synthetic accessibility , 2007, J. Comput. Aided Mol. Des..
[21] William T. Scherer,et al. "The desirability function: underlying assumptions and application implications" , 1998, SMC'98 Conference Proceedings. 1998 IEEE International Conference on Systems, Man, and Cybernetics (Cat. No.98CH36218).
[22] P. Leeson,et al. The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.
[23] Stephen R. Johnson,et al. Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.
[24] Young Bin Choy,et al. The Rule of Five for Non-Oral Routes of Drug Delivery: Ophthalmic, Inhalation and Transdermal , 2011, Pharmaceutical Research.
[25] K. Stewart,et al. Drug Guru: a computer software program for drug design using medicinal chemistry rules. , 2006, Bioorganic & medicinal chemistry.
[26] W. Guida,et al. The art and practice of structure‐based drug design: A molecular modeling perspective , 1996, Medicinal research reviews.
[27] Johann Gasteiger,et al. A Graph-Based Genetic Algorithm and Its Application to the Multiobjective Evolution of Median Molecules. , 2004 .
[28] Johann Gasteiger,et al. A novel workflow for the inverse QSPR problem using multiobjective optimization , 2006, J. Comput. Aided Mol. Des..
[29] Sean Ekins,et al. Evolving molecules using multi-objective optimization: applying to ADME/Tox. , 2010, Drug discovery today.
[30] Joelle M. R. Gola,et al. Focus on success: using a probabilistic approach to achieve an optimal balance of compound properties in drug discovery , 2006, Expert opinion on drug metabolism & toxicology.
[31] Brett A Tounge,et al. The role of molecular size in ligand efficiency. , 2007, Bioorganic & medicinal chemistry letters.
[32] Ryan H. Lilien,et al. Applying Medicinal Chemistry Transformations and Multiparameter Optimization to Guide the Search for High-Quality Leads and Candidates , 2011, J. Chem. Inf. Model..
[33] C. Abad-Zapatero,et al. Ligand efficiency indices for effective drug discovery , 2007, Expert opinion on drug discovery.
[34] Gerhard Klebe,et al. Adding calorimetric data to decision making in lead discovery: a hot tip , 2010, Nature Reviews Drug Discovery.
[35] Thomas Bäck,et al. Combining Aggregation with Pareto Optimization: A Case Study in Evolutionary Molecular Design , 2009, EMO.
[36] György M. Keserü,et al. The influence of lead discovery strategies on the properties of drug candidates , 2009, Nature Reviews Drug Discovery.
[37] T. Ritchie,et al. The impact of aromatic ring count on compound developability--are too many aromatic rings a liability in drug design? , 2009, Drug discovery today.
[38] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.
[39] A. Chadwick,et al. Overcoming psychological barriers to good discovery decisions. , 2010, Drug discovery today.
[40] D J Rogers,et al. A Computer Program for Classifying Plants. , 1960, Science.
[41] B. E. Evans,et al. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. , 1988, Journal of medicinal chemistry.
[42] Peter J. Fleming,et al. Combinatorial Library Design Using a Multiobjective Genetic Algorithm , 2002, J. Chem. Inf. Comput. Sci..
[43] E. Débiton,et al. Cytotoxic effects of 110 reference compounds on HepG2 cells and for 60 compounds on HeLa, ECC-1 and CHO cells. II mechanistic assays on NAD(P)H, ATP and DNA contents. , 2005, Toxicology in vitro : an international journal published in association with BIBRA.
[44] G. Derringer,et al. Simultaneous Optimization of Several Response Variables , 1980 .
[45] Charles C. Persinger,et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.
[46] D. Rogers,et al. Using Extended-Connectivity Fingerprints with Laplacian-Modified Bayesian Analysis in High-Throughput Screening Follow-Up , 2005, Journal of biomolecular screening.
[47] M. Edwards,et al. Using the Golden Triangle to optimize clearance and oral absorption. , 2009, Bioorganic & medicinal chemistry letters.
[48] I. Kola,et al. Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.
[49] W. Jaffe. Pareto Translated: A Review Article , 1972 .
[50] Phillip Jeffrey,et al. The Practice of Medicinal Chemistry , 2004 .
[51] P. Verhoest,et al. Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. , 2010, ACS chemical neuroscience.